Phase III prevention trial showed subcutaneous administration of investigational antibody cocktail casirivimab and imdevimab reduced risk of symptomatic COVID-19 infections by 81%

? | Casirivimab and imdevimab (1,200 mg subcutaneous dose) | Placebo |
n=753 | n=752 | |
Proportion of subjects with symptomatic SARS-CoV-2 infections through day 29 (primary endpoint) | ||
Risk reduction | 81% (p<0.0001) | |
# of patients with events | 11 (1.5%) | 59 (7.8%) |
Symptoms and viral load | ||
Total weeks with symptoms | ||
Reduction | 93% (p<0.0001) | |
Total # of weeks (cumulative for all individuals in each arm) | 13 | 188 |
# of weeks with symptoms (mean) in symptomatic individuals | 1.2 | 3.2 |
Total weeks with high viral load (>104?copies/mL) | ||
Reduction | 90% (p<0.0001) | |
Total # of weeks (cumulative for all individuals in each arm) | 14 | 136 |
# of weeks with high viral load (mean) in qPCR positive subjects | 0.4 | 1.3 |
? | Casirivimab and imdevimab (single 1,200 mg dose) | Placebo |
n=100 | n=104 | |
Proportion of subjects with symptomatic SARS-CoV-2 infections through day 29 (primary endpoint) | ||
Risk reduction | 31% (p=0.0380) | |
# of patients with events (cumulative for all individuals in each arm) | 29 (29%) | 44 (42%) |
Symptoms, viral load and COVID-19 related events | ||
Total weeks with symptoms | ||
Reduction | 45% (p=0.0273) | |
Total # of weeks (cumulative for all individuals in each arm) | 90 | 170 |
Total weeks with high viral load (>104?copies/mL) | ||
Reduction | 40% (p=0.001) | |
Total # of weeks | 48 | 82 |
Dr. Nicolas Dunant Phone: +41 61 687 05 17 | Patrick Barth Phone: +41 61 688 44 86 |
Dr. Daniel Grotzky Phone: +41 61 688 31 10 | Karsten Kleine Phone: +41 61 682 28 31 |
Nina M?hlitz Phone: +41 79 327 54 74 | Nathalie Meetz Phone: +41 61 687 43 05 |
Dr. Barbara von Schnurbein Phone: +41 61 687 89 67 |
Roche Investor Relations | |
Dr. Karl Mahler Phone: +41 61 68-78503 e-mail:?karl.mahler@roche.com | Jon Kaspar Bayard Phone: +41 61 68-83894 e-mail:?jon_kaspar.bayard@roche.com |
Dr. Sabine Borngr?ber Phone: +41 61 68-88027 e-mail:?sabine.borngraeber@roche.com | Dr. Bruno Eschli Phone: +41 61 68-75284 e-mail:?bruno.eschli@roche.com |
Dr. Birgit Masjost Phone: +41 61 68-84814 e-mail:?birgit.masjost@roche.com | Dr. Gerard Tobin Phone: +41 61 68-72942 e-mail:?gerard.tobin@roche.com |
? | |
Investor Relations North America | |
Loren Kalm Phone: +1 650 225 3217 e-mail:?kalm.loren@gene.com | Dr. Lisa Tuomi Phone: +1 650 467 8737 e-mail:?tuomi.lisa@gene.com |